Pharvaris

• Pharvaris, a late-stage biotechnology company focused on developing oral treatments for hereditary angioedema successfully raised USD 201 million in equity financing
• Capital increase of 8,250,000 new ordinary shares and 1,312,500 additional new ordinary shares (related to the full exercise of the underwriters’ option) at a price of USD 20.00 per share alongside pre-funded warrants to purchase 500,000 ordinary shares at a price of USD 19.99 per pre-funded warrant, generating gross proceeds of USD 201 million for Pharvaris at a discount of 13.5% to the pre-launch closing price
• The transaction was launched on the back of positive momentum in the HAE space and Pharvaris’ announcement expecting to pull the topline read-out of its RAPIDe-3 study six months forward to Q4 2025
• Pharvaris intends to use the net proceeds of this offering primarily to fund its late stage clinical programs and commercialisation-related expenses
• Van Lanschot Kempen acted as Joint Bookrunner and the only European Bank in a US-dominated banking syndicate and is proud to have continuously supported Pharvaris after being involved in its 2021 US IPO

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Lead Manager in the USD 345 million capital increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank